CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (78,789)	$ (55,223)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	20,173	19,158
Allowance for credit losses and inventory reserves	460	619
Share-based compensation, including restructuring costs	32,226	37,502
Amortization of discount and cost of issuance of debt	1,354	516
Asset impairment in relation to restructuring	3,231	0
Gain from change in fair value of contingent considerations and acquisition-related holdbacks	(4,893)	(32,690)
Loss (Gain) from change in fair value of currency forward contract	(1,370)	1,209
Gain from extinguishment of debt	(2,623)	0
Amortization of right-of-use assets	1,579	1,656
Changes in operating assets and liabilities:
Accounts receivable	(5,609)	5,459
Inventory	4,199	(5,772)
Accounts payable	(8,853)	5,654
Accrued expenses and other current liabilities	(1,988)	(4,415)
Accrued payroll liabilities	3,084	914
Prepaid, other current and noncurrent assets	1,389	(976)
Operating lease liabilities	(1,358)	(1,598)
Other long-term liabilities	1,182	(1,086)
Net cash used in operating activities	(36,606)	(29,073)
Cash flows from investing activities:
Purchases of property and equipment	(8,392)	(5,979)
Business combinations, net of cash acquired	0	(3,200)
Net cash used in investing activities	(8,392)	(9,179)
Cash flows from financing activities:
Proceeds from issuance of common stock/At-the-market offering	0	2,318
Proceeds from issuance of debt obligations	0	10,404
Issuance costs on line of credit	(50)	(50)
Payments on debt obligations	(905)	(1,710)
Repurchase of debt obligations	(26,829)	0
Payments on financed software	(3,691)	(4,429)
Deferred payments on business combination	(2,534)	0
Proceeds from exercise of stock options	1	25
Net cash provided by (used in) financing activities	(34,008)	6,558
Effect of exchange rate changes on cash and cash equivalents	(2,689)	2,663
Net decrease in cash and cash equivalents	(81,695)	(29,031)
Cash, cash equivalents and restricted cash at beginning of period	284,548	151,678
Cash, cash equivalents and restricted cash at end of period	202,853	122,647
Reconciliation of amounts on condensed consolidated balance sheet:
Cash and cash equivalents	192,560	112,347
Restricted cash	10,293	10,300
Total cash, cash equivalents and restricted cash	202,853	122,647
Supplemental disclosure of cash flow information:
Cash paid for interest	7,942	3,728
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	(243)	3,336
Fair value of common stock issued to satisfy contingent considerations and acquisition-related holdbacks	0	47,211
Contingent consideration for business combination	0	4,599
Accrual for purchase consideration for business combination	0	1,300
Fair value of common stock issued for investment in Expedera	$ 0	$ 3,428